ACTA2

Across TCGA pan-cancer cohorts, ACTA2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTA2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ACTA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACTA2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where ACTA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	II,III,IV	0.928	1.000	.017	10	view →
LUAD	DFS	Tertile	II,III,IV	0.844	0.949	.012	6	view →
GBM	OS	Tertile	All	0.959	0.740	.034	1	view →
LSCC	DFS	Median	II,III,IV	0.674	0.877	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTA2–HNSC (OS)

Open the HNSC breakdown →